Quantifying infection risks in incompatible living donor kidney transplant recipients

Quantifying infection risks in incompatible living donor kidney transplant recipients

Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of transplantation 2021-04, Vol.21 (4), p.1564-1575
Hauptverfasser: Avery, Robin K., Motter, Jennifer D., Jackson, Kyle R., Montgomery, Robert A., Massie, Allan B., Kraus, Edward S., Marr, Kieren A., Lonze, Bonnie E., Alachkar, Nada, Holechek, Mary J., Ostrander, Darin, Desai, Niraj, Waldram, Madeleine M., Shoham, Shmuel, Steinke, Seema Mehta, Subramanian, Aruna, Hiller, Janet M., Langlee, Julie, Young, Sheila, Segev, Dorry L., Garonzik Wang, Jacqueline M.
Format: Artikel
Sprache:eng
Schlagworte:
ABO Blood-Group System
ABO system
Blood Group Incompatibility
clinical research / practice
desensitization
Desensitization (Psychology)
Graft Rejection - epidemiology
Graft Rejection - etiology
Graft Survival
Histocompatibility antigen HLA
Humans
Immunomodulation
infection and infectious agents
Infections
infectious disease
Kidney transplantation
Kidney Transplantation - adverse effects
kidney transplantation / nephrology
kidney transplantation: living donor
Kidney transplants
Living Donors
Morbidity
Original
ORIGINAL ARTICLES
Statistical analysis
Transplant Recipients
Transplants & implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/compatible (n = 260), low (0‐4 plasmaphereses, n = 47), moderate (5‐9, n = 74), and high (≥10, n = 94). The 1‐year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high‐intensity desensitization (P 
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.16316